📰 Eric Elenko News
Page 5 - Eric Elenko News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Eric Elenko. Real-time updates on events, politics, business and more.
April 21, 2023
Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) COO Andrew Craig Miller sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, April 18th. The shares were sold at an average price of $200.16, for a total value of $6,004,800.00. Following the transaction, the chief operating officer now owns 30,900 shares of the company’s […]
April 20, 2023
Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) was the target of a significant growth in short interest in March. As of March 31st, there was short interest totalling 2,140,000 shares, a growth of 22.3% from the March 15th total of 1,750,000 shares. Based on an average daily volume of 389,900 shares, the days-to-cover ratio is […]
April 8, 2023
Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) Director Laurie J. Olson sold 1,000 shares of the firm’s stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $181.02, for a total value of $181,020.00. The transaction was disclosed in a legal filing with the SEC, which is accessible […]
April 6, 2023
Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) Director Laurie J. Olson sold 1,000 shares of the company’s stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $181.02, for a total value of $181,020.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which […]
April 2, 2023
Shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) have been assigned a consensus rating of “Moderate Buy” from the sixteen analysts that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating on the company. The average 12 […]
April 1, 2023
Karuna Therapeutics (NASDAQ:KRTX – Get Rating) had its price target cut by HC Wainwright from $320.00 to $300.00 in a report issued on Tuesday morning, The Fly reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Karuna Therapeutics’ Q1 2023 earnings at ($2.61) EPS, Q2 2023 earnings at […]
April 1, 2023
Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) – Equities research analysts at HC Wainwright upped their Q1 2023 earnings estimates for shares of Karuna Therapeutics in a report issued on Tuesday, March 28th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($2.61) per share for the quarter, up from […]
March 31, 2023
Moody Aldrich Partners LLC raised its holdings in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) by 18.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,055 shares of the company’s stock after buying an additional 2,816 shares during the […]
March 30, 2023
Karuna Therapeutics (NASDAQ:KRTX – Get Rating) had its price objective cut by analysts at HC Wainwright from $320.00 to $300.00 in a note issued to investors on Tuesday, The Fly reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 66.09% from the stock’s previous […]
March 30, 2023
Catalyst Private Wealth LLC grew its stake in Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) by 50.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 21,837 shares of the company’s stock after acquiring an additional 7,361 shares during the quarter. Karuna Therapeutics comprises […]